Papers - Enoki, Yuki

Application of epithelial lining fluid drug concentrations to MIC(i)-Based PK/PD modeling of cefepime/nacubactam in a murine model of CPE pneumonia.

Mizukami Y, Takahashi M, Suzuki K, Duan S, Ikegami S, Muraishi T, Satake N, Okamoto Y, Igarashi Y, Enoki Y, Taguchi K, Matsumoto K

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 32 ( 1 ) 102889 2026.01

ISSN  1341-321X

• Access to Document (DOI)

Impact of Chronic Kidney Disease on the Onset of Sepsis: A Systematic Review

Osa Sumika, Enoki Yuki, Endo Ayuka, Kumamoto Kanako, Kobayashi Keita, Komiya Chihiro, Satake Natsuki, Kawakami Junichi, Yagi Tatsuya, Taguchi Kazuaki, Matsumoto Kazuaki

Biological and Pharmaceutical Bulletin (The Pharmaceutical Society of Japan)  49 ( 1 ) 99 - 107 2026

ISSN  0918-6158

　View Summary

<p>Patients with chronic kidney disease (CKD) who develop sepsis experience worse prognoses; however, the impact of CKD on the incidence of sepsis has not been systematically investigated. A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A comprehensive search of Medical Literature Analysis and Retrieval System Online, Web of Science, the Cochrane Register of Controlled Trials, and ClinicalTrials.gov was performed for literature published prior to May 22, 2025, comparing the onset of sepsis in patients with or without CKD. The risk of bias was determined using the Risk of Bias in Nonrandomized Studies of Interventions tool. This study was registered with the International Prospective Register of Systematic Reviews (CRD42023465075). A total of 14 studies met the inclusion criteria for the systematic review. Of these, 5 examined community-acquired sepsis, 2 focused on intensive care unit-acquired sepsis, and the rest investigated surgery-acquired sepsis. Most studies enrolled populations aged over 65 years; 2 assessed age-related sepsis risk. One study evaluated sepsis occurrence in patients with end-stage CKD, while 3 studies stratified this association by estimated glomerular filtration rate (eGFR). Nearly all studies demonstrated an increased risk of sepsis among patients with CKD, with the risk progressively increasing as eGFR declined. Additionally, 2 studies reported that CKD elevated the risk of sepsis regardless of age, and all included studies indicated a low risk of bias. We indicate that patients with CKD may have a higher risk of developing sepsis than individuals without CKD.</p>

• Access to Document (DOI)
• CiNii Research

Development and external validation of a population pharmacokinetic model and optimal Vancomycin dosing regimen for overweight and obese patients.

Komatsu T, Tomizawa A, Samura M, Suzuki A, Ishigo T, Fujii S, Ibe Y, Yoshida H, Tanaka H, Fujihara H, Yamaguchi F, Ebihara F, Maruyama T, Yagi Y, Hamada Y, Nagumo F, Takuma A, Chiba H, Nishi Y, Igarashi Y, Enoki Y, Otori K, Matsumoto K

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 31 ( 12 ) 102838 2025.12

ISSN  1341-321X

• Access to Document (DOI)

Oral β-lactam combinations are effective in vitro against Mycobacterium avium, regardless of clarithromycin susceptibility.

Yoshikawa M, Nishimura T, Misawa K, Shimamura R, Suzuki K, Kashimura S, Igarashi Y, Enoki Y, Taguchi K, Hasegawa N, Namkoong H, Matsumoto K

Microbiology spectrum 13 ( 11 ) e0201225 2025.11

• Access to Document (DOI)

Evaluating the necessity of two-point sampling for vancomycin area under the curve in follow-up therapeutic drug monitoring.

Suzuki A, Fujihara H, Yamaguchi F, Yoshida H, Tanaka H, Yagi Y, Maruyama T, Hamada Y, Ishigo T, Fujii S, Nagumo F, Samura M, Chiba H, Ebihara F, Takuma A, Komatsu T, Tomizawa A, Nishi Y, Igarashi Y, Enoki Y, Matsumoto K

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 31 ( 11 ) 102821 2025.11

ISSN  1341-321X

• Access to Document (DOI)

Prediction of treatment success in patients with Enterococcus faecium bacteremia using vancomycin AUC(24)/MIC ratio: A multicenter retrospective study.

Hanai Y, Matsumoto K, Hanawa K, Endo A, Hashi H, Miyazaki T, Yamaguchi T, Harada S, Yokoo T, Uekusa S, Yokoyama Y, Maruyama R, Tsujimura S, Asakawa D, Namiki T, Isoda R, Enoki Y, Taguchi K, Matsuo K

Diagnostic microbiology and infectious disease 113 ( 2 ) 116961 2025.10

ISSN  0732-8893

• Access to Document (DOI)

Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials.

Kawasaki A, Shintani R, Takao R, Nakazawa Y, Mihara T, Ikegami S, Shimada S, Matsumoto Y, Okamoto Y, Igarashi Y, Enoki Y, Taguchi K, Matsumoto K

Medical mycology 63 ( 10 )  2025.09

ISSN  1369-3786

• Access to Document (DOI)

Risk stratification of AUC upward deviation in patients with low serum creatinine levels treated with vancomycin: a multicenter retrospective study.

Ishigo T, Suzuki A, Ibe Y, Fujii S, Fukudo M, Yoshida H, Tanaka H, Fujihara H, Yamaguchi F, Ebihara F, Maruyama T, Hamada Y, Samura M, Nagumo F, Komatsu T, Tomizawa A, Takuma A, Chiba H, Nishi Y, Enoki Y, Taguchi K, Matsumoto K

The Journal of pharmacy and pharmacology 77 ( 9 ) 1255 - 1263 2025.09

ISSN  0022-3573

• Access to Document (DOI)

CKD-Induced Oxidative Twitch Muscle Atrophy Is Mediated by TGF- β.

Homma K, Enoki Y, Taguchi K, Matsumoto K

Kidney360 6 ( 9 ) 1438 - 1447 2025.09

ISSN  2641-7650

• Access to Document (DOI)

Establishment and validation of downsized hollow-fibre infection model and pharmacokinetics/pharmacodynamics analysis of VAN on Enterococcus faecium.

Hayashi Y, Takahashi M, Sasaki M, Suzuki K, Mizukami Y, Liu X, Enoki Y, Taguchi K, Yamaguchi T, Tateda K, Matsumoto K

The Journal of antimicrobial chemotherapy 80 ( 8 ) 2092 - 2099 2025.08

ISSN  0305-7453

• Access to Document (DOI)

Shortening the interval between the first and the second dose of vancomycin facilitates rapid achievement of the target AUC without increasing the risk of acute kidney injury, provided the AUC on the second day is appropriately controlled: a multicenter retrospective study.

Ishigo T, Suzuki A, Ibe Y, Fujii S, Fukudo M, Yoshida H, Tanaka H, Fujihara H, Yamaguchi F, Ebihara F, Maruyama T, Hamada Y, Yagi Y, Samura M, Nagumo F, Komatsu T, Tomizawa A, Takuma A, Chiba H, Nishi Y, Enoki Y, Taguchi K, Matsumoto K

Journal of pharmaceutical health care and sciences 11 ( 1 ) 44 2025.05

ISSN  2055-0294

• Access to Document (DOI)

Combined dual β-lactams and diazabicyclooctane β-lactamase inhibitor is highly effective against Mycobacterium abscessus species in vitro.

Misawa K, Nishimura T, Yoshikawa M, Shimamura R, Kashimura S, Enoki Y, Taguchi K, Matsumoto K, Hasegawa N

Journal of global antimicrobial resistance 42   142 - 150 2025.05

ISSN  2213-7165

• Access to Document (DOI)

External validation of a flowchart related to achieving the target area under the concentration-time curve for vancomycin: A retrospective multicenter study.

Ishigo T, Suzuki A, Ibe Y, Fujii S, Fukudo M, Yoshida H, Tanaka H, Fujihara H, Yamaguchi F, Ebihara F, Maruyama T, Yagi Y, Hamada Y, Samura M, Nagumo F, Komatsu T, Tomizawa A, Takuma A, Chiba H, Nishi Y, Igarashi Y, Enoki Y, Matsumoto K

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 31 ( 5 ) 102701 2025.05

ISSN  1341-321X

• Access to Document (DOI)

Influence factors of metronidazole-related CNS disorders: an analysis of the Japan adverse drug event report and FDA adverse event reporting system

Keisuke Takada, Yuki Enoki, Masaru Samura, Yuki Igarashi, Kazuaki Taguchi, Koji Tanikawa, Kazuaki Matsumoto

Expert Opinion on Drug Safety (Informa UK Limited)     1 - 7 2025.04

ISSN  1474-0338

• Access to Document (DOI)

Pharmacists’ Awareness and Support for Common-use Pharmaceuticals: A Survey Study

Okamoto Yuko, Taguchi Kazuaki, Enoki Yuki, Hori Satoko, Yamaura Katsunori, Matsumoto Kazuaki

Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) (Japanese Society of Pharmaceutical Health Care and Sciences)  51 ( 4 ) 196 - 202 2025.04

ISSN  1346-342X

　View Summary

<p>The Japan Pharmaceutical Association proposed a new category of over-the-counter (OTC) drugs, tentatively termed “common-use pharmaceuticals for both medical and general use,” in their “Policy Proposal 2022.” This new category will be classified as “Class 0,” meaning the risk classification will remain unchanged. Consequently, pharmacists will be responsible for providing information and selling these products. Understanding pharmacists’ perceptions of this policy proposal is crucial for developing a framework for this new category; however, no relevant evidence exists. Therefore, this study conducted a web-based, anonymous, self-administered questionnaire survey targeting pharmacists in hospitals, health insurance pharmacies, and drugstores to investigate their awareness and views on the proposal. The results revealed that less than 30％ of the pharmacists, regardless of their job role (hospital, health insurance pharmacy, or drugstore), were aware of the proposal, indicating a low level of awareness. However, regardless of their awareness at the time of the survey, more than half of the respondents expressed support for establishing these common-use pharmaceuticals, with few opposing the idea. Many pharmacists identified cold remedies, antitussives/expectorants, antipyretic analgesics, digestive medications, topical medications (<i>eg</i>, patches), and allergy medications as medical drugs that should be classified under the new category. This study is the first to offer insight into pharmacist awareness and views regarding the establishment of common-use pharmaceuticals, providing evidence for future discussions.</p>

• Access to Document (DOI)
• CiNii Research

Direct comparison of the effects of first- and second-generation H(1) -receptor blockers on motor functions in mice.

Taguchi K, Tenjin K, Sakamoto Y, Shimada A, Hara R, Iketani O, Okamoto Y, Enoki Y, Kizu J, Hori S, Matsumoto K

Die Pharmazie 80 ( 1 ) 24 - 28 2025.03

ISSN  0031-7144

• Access to Document (DOI)

Development and validation of a population pharmacokinetic model of vancomycin for patients of advanced age.

Takada K, Samura M, Igarashi Y, Suzuki A, Ishigo T, Fujii S, Ibe Y, Yoshida H, Tanaka H, Ebihara F, Maruyama T, Hamada Y, Komatsu T, Tomizawa A, Takuma A, Chiba H, Yagi Y, Nishi Y, Enoki Y, Taguchi K, Tanikawa K, Kunishima H, Matsumoto K

Journal of pharmaceutical health care and sciences 11 ( 1 ) 18 2025.03

ISSN  2055-0294

• Access to Document (DOI)

Reply to Mitsuboshi, "Enhancing result reliability by addressing potential confounding factors".

Tomoyuki Ishigo, Kazuaki Matsumoto, Hiroaki Yoshida, Hiroaki Tanaka, Yuta Ibe, Satoshi Fujii, Masahide Fukudo, Hisato Fujihara, Fumihiro Yamaguchi, Fumiya Ebihara, Takumi Maruyama, Yukihiro Hamada, Masaru Samura, Fumio Nagumo, Toshiaki Komatsu, Atsushi Tomizawa, Akitoshi Takuma, Hiroaki Chiba, Yoshifumi Nishi, Yuki Enoki, Kazuaki Taguchi, Ayako Suzuki

Microbiology spectrum 13 ( 3 ) e0149924 2025.03

• Access to Document (DOI)

Carbon monoxide alleviates endotoxin-induced acute lung injury via NADPH oxidase inhibition in macrophages and neutrophils.

Watabe Y, Giam Chuang VT, Sakai H, Ito C, Enoki Y, Kohno M, Otagiri M, Matsumoto K, Taguchi K

Biochemical pharmacology 233   116782 2025.03

ISSN  0006-2952

• Access to Document (DOI)

Treatment success prediction in patients with methicillin-resistant coagulase-negative staphylococci infections, using vancomycin AUC24/MIC ratio: a multicentre retrospective cohort study.

Yuki Hanai, Kazuaki Matsumoto, Aiju Endo, Kazumi Hanawa, Hideki Hashi, Taito Miyazaki, Tetsuo Yamaguchi, Sohei Harada, Takuya Yokoo, Shusuke Uekusa, Daiki Asakawa, Yoshiaki Yokoyama, Riku Maruyama, Shun Tsujimura, Takaya Namiki, Ryo Isoda, Yuki Enoki, Kazuaki Taguchi, Kazuhiro Matsuo

The Journal of antimicrobial chemotherapy 80 ( 2 ) 538 - 546 2025.02

ISSN  0305-7453

　View Summary

BACKGROUND: Although vancomycin is commonly used to treat methicillin-resistant coagulase-negative staphylococci (MRCoNS) infections, there are no clear guidelines for the optimal 24 h AUC24/MIC ratio. This study aimed to determine the target AUC24/MIC ratio associated with vancomycin-treated MRCoNS infection outcomes. METHODS: This multicentre retrospective cohort study included adult patients who received vancomycin for ≥5 days for bloodstream infections caused by MRCoNS between January 2018 and December 2023. Primary outcome was treatment success, defined as a composite of survival beyond 30 days, clinical success and microbiological eradication. Secondary outcomes included 30-day mortality, clinical success, microbiological eradication and nephrotoxicity. Receiver operating characteristic (ROC) curve analysis was used to identify the AUC24/MIC cut-off for treatment success. Multivariate regression analysis was used to determine the association between AUC24/MIC and outcomes. RESULTS: This study included 147 patients. ROC analysis identified a target AUC24/MIC ≥373 for treatment success. The overall treatment success rate (70.1%) was significantly higher in the above-average AUC24/MIC cut-off group (83.1%) than that in the below AUC24/MIC cut-off group (57.9%). Multivariate analysis confirmed that AUC24/MIC ≥373 was an independent predictor (adjusted OR = 10.227; 95% CI = 3.585-29.171). The 30-day mortality and microbiological eradication rates differed significantly between the below- and above-cut-off groups, whereas nephrotoxicity rates were comparable among the groups. CONCLUSIONS: In treating MRCoNS infections, vancomycin AUC24/MIC ratio ≥373 was independently associated with favourable treatment outcomes. However, further prospective studies are required to confirm this target owing to the retrospective nature of this study.

• Access to Document (DOI)